Compare McKesson Corporation (MCK) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McKesson Corporation vs Wendys Co — how do they compare? McKesson Corporation trades at $901.3 (market cap $105.14B), while Wendys Co trades at $7.68 (market cap $1.44B). The key difference: McKesson Corporation is far larger — about 73× Wendys Co's market cap, and Wendys Co pays the higher dividend (3.71%). Which is the better fit depends on your goals.
| MCK | WEN | |
|---|---|---|
Market Cap | $105.14B | $1.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $995.69 | $10.68 |
52-Week Low | $659.01 | $6.17 |
Enterprise Value | $111.67B | $5.17B |
Dividend Yield | 0.42% | 3.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $879.87, up 1.18% today, with strong momentum from recent earnings beats and raised guidance. The stock shows bullish technical signals, supported by robust revenue growth and solid cash flow generation. Recent news highlights strength in specialty drugs and oncology, driving positive sentiment.
Outlook remains favorable with a consensus price target of $990.67, though thin profit margins and high liabilities pose risks. Continued execution on growth initiatives and cost discipline are key for sustained upside, while macroeconomic pressures and competitive dynamics require monitoring.
Wendy's stock (WEN) trades at $7.30, down 5.07% amid significant operational challenges. The company faces declining U.S. traffic, a 50% dividend cut, and loss of its position as America's second-largest burger chain to Burger King. Despite beating Q2 2026 EPS estimates ($0.18 vs. $0.16 expected), revenue trends remain weak with profit margins contracting from 7.58% in 2025 to 5.72% projected for 2026. Technical indicators show bearish momentum with key support at $7.00.
The outlook remains challenging as new CEO Bob Wright implements a turnaround strategy. While valuation appears reasonable (P/E 11.44, P/S 0.65), execution risks are elevated given competitive pressures and $2.66 billion debt load. Analyst sentiment is mixed with 62.75% hold ratings, reflecting uncertainty about the company's ability to regain market share and improve franchisee economics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
